While the positive selection for EpCAM is useful for most epithelial cancers, it is not suitable for glioblastoma because neural tumors usually lack EpCAM expression, but it has potential for glioblastoma, when the right markers will be applied; Specific CD44 variants may be an option [23]. Here, EPCAM is linked to glioblastoma.